Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lurdes Zamora

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Blood Advances|September 1, 2021
Engraftment characterization of risk-stratified AML in NSGS miceRafael Díaz de la Guardia, Talía Velasco-Hernandez, Francisco Gutiérrez-Agüera, et al.
Genes, Chromosomes & Cancer|July 25, 2019
Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemiaJordi Ribera, Lurdes Zamora, Mireia Morgades, et al.
British Journal of Haematology|May 26, 2018
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemiaAna M Hurtado, Gines Luengo-Gil, Tzu H Chen-Liang, et al.
British Journal of Haematology|October 18, 2019
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemiaLaura Palomo, Mariam Ibáñez, María Abáigar, et al.
European Journal of Haematology|September 5, 2022
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogeneticsJohana Díaz-Santa, Rocío Rodríguez-Romanos, Rosa Coll, et al.
Scientific Reports|November 6, 2020
Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesisMarta Isidro-Hernández, Andrea Mayado, Ana Casado-García, et al.
European Journal of Haematology|September 6, 2015
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemiaBlanca Xicoy, Ulrich Germing, María-José Jimenez, et al.
Cell Reports. Medicine|December 20, 2023
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapyLaura Hurtado-Navarro, Ernesto José Cuenca-Zamora, Lurdes Zamora, et al.
Blood Advances|December 15, 2021
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocolAlex Bataller, Ana Garrido, Francesca Guijarro, et al.
Blood Advances|July 10, 2026
Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasmsOriol Calvete, Julia Mestre, Lorea Chaparro-González, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Blood Advances|September 1, 2021
Engraftment characterization of risk-stratified AML in NSGS miceRafael Díaz de la Guardia, Talía Velasco-Hernandez, Francisco Gutiérrez-Agüera, et al.
Genes, Chromosomes & Cancer|July 25, 2019
Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemiaJordi Ribera, Lurdes Zamora, Mireia Morgades, et al.
British Journal of Haematology|May 26, 2018
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemiaAna M Hurtado, Gines Luengo-Gil, Tzu H Chen-Liang, et al.
British Journal of Haematology|October 18, 2019
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemiaLaura Palomo, Mariam Ibáñez, María Abáigar, et al.
European Journal of Haematology|September 5, 2022
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogeneticsJohana Díaz-Santa, Rocío Rodríguez-Romanos, Rosa Coll, et al.
Scientific Reports|November 6, 2020
Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesisMarta Isidro-Hernández, Andrea Mayado, Ana Casado-García, et al.
European Journal of Haematology|September 6, 2015
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemiaBlanca Xicoy, Ulrich Germing, María-José Jimenez, et al.
Cell Reports. Medicine|December 20, 2023
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapyLaura Hurtado-Navarro, Ernesto José Cuenca-Zamora, Lurdes Zamora, et al.
Blood Advances|December 15, 2021
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocolAlex Bataller, Ana Garrido, Francesca Guijarro, et al.
Blood Advances|July 10, 2026
Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasmsOriol Calvete, Julia Mestre, Lorea Chaparro-González, et al.
Pageof 7